Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 150 mg - capsule, hard - excipient ingredients: titanium dioxide; maize starch; sodium lauryl sulfate; colloidal anhydrous silica; patent blue v; lactose monohydrate; gelatin; purified talc - treatment of vaginal candidiasis.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nifedipine, quantity: 60 mg - tablet, modified release - excipient ingredients: iron oxide red; titanium dioxide; hypromellose; magnesium stearate; povidone; purified talc; macrogol 4000; carbomer 934p; lactose monohydrate; colloidal anhydrous silica; basic butylated methacrylate copolymer - treatment of hypertension. prophylaxis of chronic stable angina pectoris.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nifedipine, quantity: 30 mg - tablet, modified release - excipient ingredients: carbomer 934p; titanium dioxide; povidone; purified talc; iron oxide red; macrogol 4000; hypromellose; magnesium stearate; colloidal anhydrous silica; lactose monohydrate; basic butylated methacrylate copolymer - treatment of hypertension. prophylaxis of chronic stable angina pectoris.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - norfloxacin, quantity: 400 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - the treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms. the treatment of adults with gastrointestional infections, in particular shigellosis and traveller's diarrhoea. note: specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants. suppression in adults of chronic, recurrent urinary tract infections.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: stearic acid; hypromellose; colloidal anhydrous silica - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, gliclazide mr 30 mg tablets, taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nicorandil, quantity: 10 mg - tablet, uncoated - excipient ingredients: povidone; cetyl alcohol; croscarmellose sodium; sodium stearylfumarate; mannitol - nicorandil is indicated for the treatment of chronic stable angina pectoris.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nicorandil, quantity: 20 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; mannitol; povidone; cetyl alcohol; sodium stearylfumarate - nicorandil is indicated for the treatment of chronic stable angina pectoris.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - mirtazapine, quantity: 45 mg - tablet, orally disintegrating - excipient ingredients: crospovidone; aspartame; colloidal anhydrous silica; mannitol; microcrystalline cellulose; magnesium stearate; flavour - treatment of major depression including relapse prevention.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - mirtazapine, quantity: 30 mg - tablet, orally disintegrating - excipient ingredients: microcrystalline cellulose; aspartame; magnesium stearate; mannitol; crospovidone; colloidal anhydrous silica; flavour - treatment of major depression including relapse prevention.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - mirtazapine, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: colloidal anhydrous silica; mannitol; microcrystalline cellulose; crospovidone; aspartame; magnesium stearate; flavour - treatment of major depression including relapse prevention.